84 related articles for article (PubMed ID: 30320608)
1. Abiraterone acetate treatment in patients with castration-resistant prostate cancer with visceral metastases: a real-world experience.
Facchini G; Cavaliere C; D'Aniello C; Iovane G; Rossetti S
Anticancer Drugs; 2019 Feb; 30(2):179-185. PubMed ID: 30320608
[TBL] [Abstract][Full Text] [Related]
2. Real-World Safety and Efficacy Outcomes with Abiraterone Acetate Plus Prednisone or Prednisolone as the First- or Second-Line Treatment for Metastatic Castration-Resistant Prostate Cancer: Data from the Prostate Cancer Registry.
Bjartell A; Lumen N; Maroto P; Paiss T; Gomez-Veiga F; Birtle A; Kramer G; Kalinka E; Spaëth D; Feyerabend S; Matveev V; Lefresne F; Lukac M; Wapenaar R; Costa L; Chowdhury S
Target Oncol; 2021 May; 16(3):357-367. PubMed ID: 33826036
[TBL] [Abstract][Full Text] [Related]
3. Impact of clinical versus radiographic progression on clinical outcomes in metastatic castration-resistant prostate cancer.
Rao A; Scher HI; De Porre P; Yu MK; Londhe A; Qi K; Morris MJ; Ryan C
ESMO Open; 2020 Nov; 5(6):e000943. PubMed ID: 33184097
[TBL] [Abstract][Full Text] [Related]
4. A Signal-finding Study of Abemaciclib in Heavily Pretreated Patients with Metastatic Castration-Resistant Prostate Cancer: Results from CYCLONE 1.
Agarwal N; Castellano D; Alonso-Gordoa T; Arranz Arija JA; Colomba E; Gravis G; Mourey L; Oudard S; Fléchon A; Gonzalez M; Maroto PM; Schweizer MT; Gallardo E; Johnston E; Balar A; Haddad N; Appiah AK; Nacerddine K; Piulats JM
Clin Cancer Res; 2024 Mar; ():. PubMed ID: 38512117
[TBL] [Abstract][Full Text] [Related]
5. Abiraterone acetate, enzalutamide and their sequence for castration-resistant prostate cancer : Adherence, survival and hospitalization analysis of a medical claims database.
Al-Ali BM; Eredics K; Madersbacher S; Schauer I
Wien Klin Wochenschr; 2018 Nov; 130(21-22):659-664. PubMed ID: 30324300
[TBL] [Abstract][Full Text] [Related]
6. Abiraterone in metastatic castration-resistant prostate cancer: Efficacy and safety in unselected patients.
Marret G; Doucet L; Hennequin C; Fizazi K; Culine S
Cancer Treat Res Commun; 2018; 17():37-42. PubMed ID: 30347333
[TBL] [Abstract][Full Text] [Related]
7. Clinical Features and Therapeutic Outcomes in Men with Advanced Prostate Cancer and DNA Mismatch Repair Gene Mutations.
Antonarakis ES; Shaukat F; Isaacsson Velho P; Kaur H; Shenderov E; Pardoll DM; Lotan TL
Eur Urol; 2019 Mar; 75(3):378-382. PubMed ID: 30337059
[TBL] [Abstract][Full Text] [Related]
8. Corticosteroid switch in heavily pre-treated castration-resistant prostate cancer patients progressed on abiraterone acetate plus prednisone.
Roviello G; Petrioli R; Bonetta A; Conca R; Rodriquenz MG; Aieta M
Invest New Drugs; 2018 Dec; 36(6):1110-1115. PubMed ID: 30345466
[TBL] [Abstract][Full Text] [Related]
9. Recent trends in the management of advanced prostate cancer.
Ritch C; Cookson M
F1000Res; 2018; 7():. PubMed ID: 30345007
[TBL] [Abstract][Full Text] [Related]
10. Lessons from the SWITCH trial: changing glucocorticoids in the management of metastatic castration-resistant prostate cancer (mCRPC).
Teo MY; Scher HI
Br J Cancer; 2018 Oct; 119(9):1041-1043. PubMed ID: 30344307
[TBL] [Abstract][Full Text] [Related]
11. Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer.
Sharp A; Coleman I; Yuan W; Sprenger C; Dolling D; Rodrigues DN; Russo JW; Figueiredo I; Bertan C; Seed G; Riisnaes R; Uo T; Neeb A; Welti J; Morrissey C; Carreira S; Luo J; Nelson PS; Balk SP; True LD; de Bono JS; Plymate SR
J Clin Invest; 2019 Jan; 129(1):192-208. PubMed ID: 30334814
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naïve prostate cancer: a subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, Phase 3 study.
Fukasawa S; Suzuki H; Kawaguchi K; Noguchi H; Enjo K; Tran N; Todd M; Fizazi K; Matsubara N
Jpn J Clin Oncol; 2018 Nov; 48(11):1012-1021. PubMed ID: 30371895
[TBL] [Abstract][Full Text] [Related]
13. Fatigue, treatment satisfaction and health-related quality of life among patients receiving novel drugs suppressing androgen signalling for the treatment of metastatic castrate-resistant prostate cancer.
Dearden L; Shalet N; Artenie C; Mills A; Jackson C; Grant L; Gater A
Eur J Cancer Care (Engl); 2019 Jan; 28(1):e12949. PubMed ID: 30408244
[TBL] [Abstract][Full Text] [Related]
14. The importance of targeting intracrinology in prostate cancer management.
Hamid ARAH; Tendi W; Sesari SS; Mochtar CA; Umbas R; Verhaegh G; Schalken JA
World J Urol; 2019 May; 37(5):751-757. PubMed ID: 30350016
[TBL] [Abstract][Full Text] [Related]
15. Plasma androgen receptor and serum chromogranin A in advanced prostate cancer.
Conteduca V; Scarpi E; Salvi S; Casadio V; Lolli C; Gurioli G; Schepisi G; Wetterskog D; Farolfi A; Menna C; De Lisi D; Burgio SL; Beltran H; Attard G; De Giorgi U
Sci Rep; 2018 Oct; 8(1):15442. PubMed ID: 30337589
[TBL] [Abstract][Full Text] [Related]
16. Alterations of tumor microenvironment by nitric oxide impedes castration-resistant prostate cancer growth.
Arora H; Panara K; Kuchakulla M; Kulandavelu S; Burnstein KL; Schally AV; Hare JM; Ramasamy R
Proc Natl Acad Sci U S A; 2018 Oct; 115(44):11298-11303. PubMed ID: 30322928
[TBL] [Abstract][Full Text] [Related]
17. Identification of subgroups of metastatic castrate-resistant prostate cancer (mCRPC) patients treated with abiraterone plus prednisone at low- vs. high-risk of radiographic progression: An analysis of COU-AA-302.
Martin LJ; Alibhai SMH; Komisarenko M; Timilshina N; Finelli A
Can Urol Assoc J; 2019 Jun; 13(6):192-200. PubMed ID: 30407155
[TBL] [Abstract][Full Text] [Related]
18. Clinical effectiveness of docetaxel for castration-sensitive prostate cancer in a real-world population-based analysis.
Lavoie JM; Zou K; Khalaf D; Eigl BJ; Kollmannsberger CK; Vergidis J; Noonan K; Zulfiqar M; Finch D; Chi KN
Prostate; 2019 Feb; 79(3):281-287. PubMed ID: 30370697
[TBL] [Abstract][Full Text] [Related]
19. Prediction of Time to Castration-Resistant Prostate Cancer Using Low-Molecular-Weight Protein Tyrosine Phosphatase Expression for Men with Metastatic Hormone-Naïve Prostate Cancer.
Miyoshi Y; Ohtaka M; Kawahara T; Ohtake S; Yasui M; Uemura K; Yoneyama S; Yokomizo Y; Uemura H; Miyamoto H; Yao M
Urol Int; 2019; 102(1):37-42. PubMed ID: 30326476
[TBL] [Abstract][Full Text] [Related]
20. Phase 2 Randomized Study of Radiation Therapy and 3-Year Androgen Deprivation With or Without Concurrent Weekly Docetaxel in High-Risk Localized Prostate Cancer Patients.
Carles J; Gallardo E; Doménech M; Font A; Bellmunt J; Figols M; Mellado B; Sáez MI; Suárez C; Méndez MJ; Maroto P; Luque R; de Portugal T; Aldabo R; Bonfill T; Morales-Barrera R; García J; Maciá S; Maldonado X; Foro P
Int J Radiat Oncol Biol Phys; 2019 Feb; 103(2):344-352. PubMed ID: 30321689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
